news

Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date CUPERTINO, Calif., July 1, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that the U.S. Food and Drug Administration (FDA) has […]

CUPERTINO, Calif., June 28, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12 at 8:00 a.m. Eastern Time.  The conference is being held at Le Parker Meridien Hotel in New York City.  Investors and analysts that

CUPERTINO, Calif., May 31, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Jefferies Healthcare Conference on Friday, June 10 at 1:30 pm Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York.  Management will also be available for

FDA’s Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016 CUPERTINO, Calif., May 19, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA)

CUPERTINO, Calif., May 11, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY‘s abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting.  The scientific poster is titled “REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation.”  Co-authors Lynn Webster and Nadav

CUPERTINO, Calif., May 5, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2016.  Total revenues were $3.6 million and net loss was $7.9 million for the three months ended March 31, 2016 as compared to total revenues of $4.8 million and net loss of $4.9 million for

CUPERTINO, Calif., April 29, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters pursuant to their option.  All of the shares in the

CUPERTINO, Calif., April 28, 2016 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2016 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

CUPERTINO, Calif., April 26, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public.  The gross proceeds to DURECT from this offering are expected to be $15 million, before deducting underwriting

CUPERTINO, Calif., April 25, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling,